Opinion|Videos|July 31, 2024
Patient Case: KRAS G12C Non–Small Cell Lung Cancer
Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
4
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
5